These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9878040)

  • 41. Potential role of autoantibody in severe neutropenia of a patient with Kawasaki Syndrome.
    Ueno K; Nomura Y; Masamoto I; Masuda K; Morita Y; Eguchi T; Okamoto Y; Kawano Y
    Scand J Immunol; 2012 Jan; 75(1):120-6. PubMed ID: 21923741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Biochemical and immunological laboratory findings in Kawasaki disease].
    Ogawa S
    Nihon Rinsho; 2008 Feb; 66(2):315-20. PubMed ID: 18260330
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Marked eosinophilia in a patient with history of severe atypical Kawasaki disease.
    O'Byrne ML; Cohen MS
    Congenit Heart Dis; 2013; 8(5):E130-3. PubMed ID: 22883471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet immune complex interaction in the pathogenesis of Kawasaki disease.
    Levin M; Holland PC; Novelli V
    Prog Clin Biol Res; 1987; 250():227-37. PubMed ID: 3423040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoreactive polymorphonuclear leukocyte elastase in complex with alpha 1-antitrypsin in Kawasaki disease.
    Inamo Y; Harada K; Okuni M; Kimoto K; Takeuchi S; Sakurabayashi I
    Acta Paediatr Jpn; 1987 Apr; 29(2):202-5. PubMed ID: 3150902
    [No Abstract]   [Full Text] [Related]  

  • 46. Spirochaetal studies in Kawasaki syndrome.
    Marchette NJ; Melish ME; James JF; Kihara S; Caplan F
    Prog Clin Biol Res; 1987; 250():87-99. PubMed ID: 3423085
    [No Abstract]   [Full Text] [Related]  

  • 47. Function of phagocytosis and intracellular killing of peripheral neutrophils in Kawasaki disease.
    Tasaka K; Hamashima Y
    Acta Pathol Jpn; 1978 Mar; 28(2):247-52. PubMed ID: 676746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased production of serum IgA-class antibody to lipid A in Kawasaki disease.
    Takeshita S; Kawase H; Shimizu T; Yoshida M; Sekine I
    Pediatr Int; 2002 Feb; 44(1):5-11. PubMed ID: 11982863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathogenesis of acute Kawasaki disease.
    Jayne DR; Lockwood CM
    Lancet; 1990 Feb; 335(8686):410-1. PubMed ID: 1968135
    [No Abstract]   [Full Text] [Related]  

  • 50. [Etiologic agent of Kawasaki disease].
    Oharaseki T; Takahashi K; Yokouchi Y; Naoe S
    Nihon Rinsho; 2008 Feb; 66(2):246-50. PubMed ID: 18260321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Study on peripheral blood mononuclear cell subpopulations in children. Part II. Peripheral blood mononuclear cell subpopulations in patients with Kawasaki disease].
    Ogiwara A
    Arerugi; 1984 Jul; 33(7):369-75. PubMed ID: 6497666
    [No Abstract]   [Full Text] [Related]  

  • 52. [Autoantibodies in patients with mucocutaneous lymph node syndrome (Kawasaki disease)].
    Saji T; Umezawa T; Hashiguchi R; Matsuo N
    Arerugi; 1983 Dec; 32(12):1129-33. PubMed ID: 6678147
    [No Abstract]   [Full Text] [Related]  

  • 53. [Factors in the development of Kawasaki disease and specificity of immunity in children].
    Matsuoka Y; Yata J
    Nihon Rinsho; 1983 Sep; 41(9):2047-51. PubMed ID: 6363750
    [No Abstract]   [Full Text] [Related]  

  • 54. [Enhanced neutrophilic functions in mucocutaneous lymph node syndrome (MCLS). With special reference to the possible role of increased active oxygen generation in the pathogenesis of coronary thromboarteritis].
    Niwa Y; Yanagida I; Somiya K
    Rinsho Ketsueki; 1984 May; 25(5):619-26. PubMed ID: 6471444
    [No Abstract]   [Full Text] [Related]  

  • 55. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease.
    Zaitsu M; Hamasaki Y; Tashiro K; Matsuo M; Ichimaru T; Fujita I; Tasaki H; Miyazaki S
    J Infect Dis; 2000 Mar; 181(3):1101-9. PubMed ID: 10720537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endothelial activation in the pathogenesis of Kawasaki disease.
    Leung DY; Cotran RS; Kurt-Jones E; Burns JC; Newburger JW; Pober JS
    Trans Assoc Am Physicians; 1989; 102():131-8. PubMed ID: 2484114
    [No Abstract]   [Full Text] [Related]  

  • 57. Mantoux test in Kawasaki disease.
    Bertotto A; Spinozzi F; Radicioni M; Vaccaro R
    Pediatrics; 1996 Jul; 98(1):161. PubMed ID: 8668395
    [No Abstract]   [Full Text] [Related]  

  • 58. The immunopathogenesis and management of Kawasaki syndrome.
    Leung DY; Schlievert PM; Meissner HC
    Arthritis Rheum; 1998 Sep; 41(9):1538-47. PubMed ID: 9751085
    [No Abstract]   [Full Text] [Related]  

  • 59. Heterophile Hanganutziu-Deicher antibodies in sera of patients with Kawasaki diseases.
    Arita K; Ikuta K; Nishi Y; Kato S; Yamauchi E; Maki S; Naiki M
    Biken J; 1982 Dec; 25(4):157-62. PubMed ID: 6897861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Complement system in immunological disease of infants and children. Part 1. The role of the complement system in Kawasaki disease].
    Kaneda Y
    Arerugi; 1983 Jul; 32(7):376-85. PubMed ID: 6639368
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.